Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Aktis Oncology (NASDAQ:AKTS) has been assigned an average recommendation of “Moderate Buy” from the eight research firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $34.60.

Several research firms have commented on AKTS. Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. upped their price target on Aktis Oncology from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Tuesday, July 14th. Raymond James Financial assumed coverage on shares of Aktis Oncology in a research report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 target price for the company. William Blair assumed coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Finally, HC Wainwright upped their price target on shares of Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd.

Aktis Oncology Trading Down 0.5%

Shares of AKTS opened at $24.89 on Friday. Aktis Oncology has a 12-month low of $14.72 and a 12-month high of $34.19. The company has a market cap of $1.33 billion and a P/E ratio of -65.50. The firm’s 50-day simple moving average is $23.38.

Aktis Oncology (NASDAQ:AKTS) last issued its quarterly earnings results on Monday, March 30th. The technology company reported ($18.17) EPS for the quarter. The firm had revenue of $1.87 million for the quarter. On average, equities research analysts expect that Aktis Oncology will post -1.64 EPS for the current year.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.